

Registered in England and Wales
Company Number 3963360

ORCHID CANCER APPEAL
'ORCHID'
ANNUAL REPORT AND FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 SEPTEMBER 2019
Charity Number 1080540

ORCHID CANCER APPEAL

INDEX TO THE ANNUAL REPORT AND FINANCIAL STATEMENTS

	Page
Title page	1
Index to the Annual Report and Financial Statements	2
Company information	3
Report of the Trustees	
Objects, Operating Context and Activities	4
Structure, Governance and Management	6
Targets and Progress	8
Financial Review	18
Future Plans	18
Formal Statements	21
Auditor's Report	22
Statement of Financial Activities	25
Balance Sheet	26
Statement of Cash flows	27
Notes to the Financial Statements	28

ORCHID CANCER APPEAL

REPORT OF THE TRUSTEES

for the year ended 30 September 2019

Registered with the Charity Commission on 3 May 2000

Company Limited by Guarantee

Charity Number 1080540

Incorporated in England Number 3963360

REGISTERED OFFICE	60 Gray's Inn Road London WC1X 8AQ
BOARD OF TRUSTEES	Mr R Lane CBE Chairman (deceased 8 February 2020) Mr C S Osborne Interim Chairman (appointed 10 March 2020) Mr W Cohen Treasurer (appointed 1 January 2020) Mr K Cook Treasurer (resigned 10 March 2020) Mr D Badenoch Mr P G Bracher Dr M Harding (resigned 9 December 2019) Mr S Harris Mr M Kibblewhite (appointed 10 March 2020) Professor RTD Oliver Mr P Norman Mr S Seymour Mr N Watkin
CHIEF EXECUTIVE	Miss R I Porta (resigned 23 April 2020) Mr A Orhan (appointed interim Chief Executive 24 April 2020)
AUDITOR	Moore Kingston Smith LLP Devonshire House 60 Goswell Road London EC1M 7AD
ACCOUNTANTS	JS2 Limited 1 Crown Square Woking Surrey GU21 6HR
LEGAL ADVISORS	Farrer & Co 66 Lincoln's Inn Fields London WC2A 3LH
BANKERS	HSBC Plc 20 Electric Parade George Lane South Woodford London E18 2LX

Orchid Cancer Appeal
60 Gray's Inn Road
London WC1X 8AQ
www.orchid-cancer.org.uk
Tel: 020 3745 7310

ORCHID CANCER APPEAL

REPORT OF THE TRUSTEES

for the year ended 30 September 2019

The Trustees, who are also directors of the charitable company, present their report for the year ended 30 September 2019, together with the financial statements covering the same period. Company Information is included as page 3.

OBJECTS, OPERATING CONTEXT AND ACTIVITIES

Objects

Over 50,000 men in the UK are diagnosed with a male specific cancer - prostate, testicular and penile cancer - every year and sadly these numbers are increasing. Orchid's aim is to provide greater knowledge and awareness about male specific cancers by funding integrated scientific and medical research into the prevention, diagnosis and treatment of these diseases, raising awareness, delivering Nurse-led services and providing eye-catching, easy to understand information about them to men and women throughout the UK, thereby helping to ensure a better quality of life for those affected.

Operating Context and Activities

In 2017 Orchid launched its three year strategy, "*The Way Ahead 2017-2020*". Our aim is to offer the best possible care and support for men and their families through awareness and education programmes, to promote better understanding of the signs and symptoms of these cancers, to encourage an early diagnosis and improved outcomes and to ensure the best possible care through our influence at a local and national level. Through funding world class research, our aim is to improve our understanding of male cancers, how they work, possible causes and to identify new treatments and enhance care. Support and information delivered by our Nurse Specialists and Community Engagement Team enables people interested in or affected by male cancers to have the best possible outcome.

The Charity is proud of the excellent progress that has been made towards "*The Way Ahead 2017-2020*" and of the many achievements during the year. We have extended our reach through our popular community Roadshow programme, training opportunities for health, social and education professionals, developing new film and video resources, services for young people at risk of testicular cancer and for men from black African and black Caribbean communities affected by, or at greater risk of prostate cancer. A further three Male Cancer Nurse Specialists joined the Charity thereby increasing our Support Services team to six Nurse Specialists and helping to meet the growing demand for support and information from those affected by or interested in male cancers.

Two of the Specialists are based in Scotland where they are delivering a dedicated Penile Cancer Support Service. Scotland has a particularly high incidence rate of the disease compared to elsewhere in the UK and low levels of awareness can lead to late diagnosis, delayed treatment and poor outcomes. Alongside developing new resources, the Nurse Specialists have run a series of community based events and presentations. They will be joined by an Information Manager at the end of December 2019.

During the year our Male Cancer Nurse Specialists and Community Engagement Team responded to 3,110 direct enquires by phone, email and face-to-face. This was an increase of 13% on the previous year reflecting increased interventions in the community and talks and presentations within community networks and workplaces. A total of 25,214 individuals accessed information about male cancer which was an increase of 11% on the previous year.

Reaching deprived and hard-to-reach communities remains a priority for the Charity. Research has shown that more deprived groups have a particularly low awareness of risk factors, signs and symptoms of cancer. Orchid Nurse Specialists together with the Community Engagement Team and volunteers ran 152 Male Cancer Awareness Roadshows, Information and Training days and awareness events in community centres, public spaces, shopping centres, healthcare settings and workplaces across the UK. These events included dedicated support and training for health, social and education professionals.

Reaching young people at risk of testicular cancer remains a priority. New resources have been developed as part of the Young Person's Testicular Cancer Project to engage health, social and education professionals and improve their understanding of testicular cancer, its signs and symptoms. These resources, developed with input from a working group of experts including students, parents, and School Nurses, complement Orchid's popular "Your Privates" testicular cancer microsite.

Orchid has continued to support black African and black Caribbean men affected by, or at risk of prostate cancer. Approximately 1 in 8 men will be diagnosed with prostate cancer in their lifetime - for black African and black Caribbean men their risk is double (1 in 4). The three year project "*Changing Lives – engaging black*

ORCHID CANCER APPEAL

REPORT OF THE TRUSTEES

for the year ended 30 September 2019

African and Caribbean men at risk of or affected by prostate cancer” generously funded by the Big Lottery, Reaching Communities Fund aims to raise awareness of the disease amongst men, their loved ones and those responsible for their care. The project has seen the delivery of community based events, awareness activities, support groups across seven London Boroughs, new partnerships and collaborations and information resources. Highlights during the year include the “One in Four” photographic project supported by Healthwatch Brent and leading photographer Paul Vickery and a new video training tool – “Letter to my unrepresented self” developed and launched to assist healthcare professionals to better support black African and black Caribbean men affected by or at risk of prostate cancer.

Study Days, Workshops and Training Sessions were delivered throughout the year - highlights include “*An Introduction to Testicular and Penile Cancer*” Study Days in partnership with the British Association of Urology Nurses (BAUN) and kindly funded by the Burdett Trust for Nursing, a series of Penile Cancer Support Meetings funded by the Big Lottery - Awards for All and “*A Cancer Survivor’s Perspective*” at the “*Improving Outcomes for People Living with and beyond Cancer*” and the “*Developing Effective Cancer Survivorship Services*” conferences.

Orchid has taken an active role in supporting Parliamentarians, Ministers and policy makers to raise the profile of male cancers and influence opinion and policy development. In October 2018 the charity held the ‘Male Cancer in Parliament’ Reception at the House of Commons which was attended by over 80 guests including researchers and healthcare professionals, representatives from the pharmaceutical industry, funders and charities. The All Party Parliamentary Group (APPG) on Male Cancer formally launched in 2019. The APPG on Male Cancer brings together the experience and expertise of clinicians, researchers, patients, carers and charities to take male cancer to the heart of Westminster. Orchid provides the Secretariat.

Orchid is committed to collaborating with the wider research community, health, social and education professionals, the NHS and other representative groups. As in previous years, the Charity worked with a range of stakeholders to identify key issues, common concerns and to work towards ensuring the best possible care and outcomes for those affected by male cancer.

There has been excellent media coverage of Orchid and male cancer during the year. The Charity has been proactive in commenting on cancer treatments, research developments, health campaigns, topical issues and in providing case studies. The annual Orchid Male Cancer Awareness Week has been the most successful campaign to date with over 790,000,000 OTS (Opportunities to See). The Week generated over 57 pieces of coverage including eight national newspaper articles and 40 pieces of news website coverage. The campaign was well supported by decision makers and influencers - 21 Members of Parliament and 13 regional MPs shared the Week and the ‘F.A.C.E up to prostate cancer’ risk factor awareness campaign on Twitter together with the NHS, Scottish government, Clinical Commissioning Groups, local councils and charities.

The ‘F.A.C.E. up to prostate cancer’ campaign has been an important and popular resource since it launched. We were delighted the campaign was the winner of the Pharmaceutical Market Excellence Awards 2018 (PMEA 2018) in the category of ‘Excellence in Engagement through Multiple Channels’.

Orchid’s research programme aims to support medical education and scientific research and encourage innovative, new ways to tackle problems that need solving. Ultimately the objective is to promote, support and accelerate step change in cancer management. Priority areas include supporting the Orchid Research Tissue Bank, clinical research, genetics, research into rare cancers and encouraging young researchers into the field of male cancer through training and career development awards. We are indebted to Professor Norman Maitland, Chairman of the Scientific Advisory Board (SAB) and the SAB members for their expertise, guidance and continued support.

The Charity is extremely grateful to the many individuals, companies, trusts, foundations, Big Lottery – Reaching Communities Fund and Awards for All who generously support our work. Without such support we could not develop new services, deliver education and awareness campaigns, and continue to meet our commitment to fighting male cancer and to supporting men, their families and all those involved in their care and well-being. Whilst much has been achieved across all areas of our work, there is no doubt that increased pressures in the funding environment have affected growth for many charities. At the time of writing this report all charities are experiencing the impact of COVID-19 and are likely to do so for some time to come.

ORCHID CANCER APPEAL

REPORT OF THE TRUSTEES

for the year ended 30 September 2019

STRUCTURE, GOVERNANCE AND MANAGEMENT

Duly registered as a Charity, Orchid is incorporated as a company, limited by guarantee, and governed by its Memorandum and Articles of Association.

Trustees are recruited on the recommendation of incumbent members of the Board, commensurate with the Chairman's aim to maintain a balanced composition. Applications from individuals seeking to become a Trustee will be considered as and when appropriate by the Board. The Board meet four times during the year and, at the Annual General Meeting, as required by the constitution, one third of the Trustees (or the nearest number thereto) retired from office in rotation, in order of longevity of appointment and were reappointed.

Trustee training and induction

On appointment, Trustees receive a comprehensive induction programme which includes a meeting with the lead programme researchers and visit to the research programmes.

In the absence of in-house provision, or an otherwise formalised programme of training, the Chief Executive advises Trustees of opportunities that will increase their general understanding of voluntary sector, healthcare and/or medical research issues. Trustees have availed themselves of these opportunities during the year.

Structure, delegation and decision-making

The decision-making process operates as follows:

- At the strategic level, the Board of Trustees regularly reviews Orchid's direction in the wider context of medical charities, requiring the Chief Executive to identify relevant key issues and present options for its consideration. Due governance remains a key requirement.
- The Finance Committee is responsible for the financial oversight of the Charity including budgeting, financial planning and monitoring as well as financial reporting and the creation and monitoring of internal controls and accounting policies. It presents a report to the Board at each of its meetings. As at the 30 September 2019, it comprised the Honorary Treasurer, Mr K Cook, Mr W Cohen, Mr R Lane CBE, Mr C Osborne, Mr S Seymour and Mr S Harris.
- Three Committees enable Trustees to apply their expertise and interest more effectively in support of the Charity's operational activity. These are the Business Development Sub-Committee, Events Sub-Committee and Projects Sub-Committee. The Committees aim to meet quarterly or as required.
- At the operational level, the Board delegates the day-to-day running of the Charity to the Chief Executive, requiring her to deliver every aspect of governance, planning and performance in accordance with the agreed strategic direction. The Board is kept apprised of personnel, awareness, the research programme and budgetary issues.

Public Benefit

The Trustees confirm that they have complied with the duty in section 17 of the Charities Act 2011 to have due regard to the Charity Commission's general guidance on public benefit including (PB2 Public Benefit: Running a Charity).

Key Management Personnel and Remuneration Policy

Orchid is committed to attracting and retaining talented staff. Staff are kept fully informed of the organisation's strategy and objectives and individual performance is reviewed throughout the year. Learning and development remain a priority and throughout the year staff attended a range of training courses and were invited to join relevant professional bodies. Temporary and volunteer personnel are engaged for specific tasks to ensure a balanced approach to managing administration, awareness campaigns, support services and fundraising.

ORCHID CANCER APPEAL

REPORT OF THE TRUSTEES

for the year ended 30 September 2019

The Key Management Personnel comprise the Trustees and the Chief Executive. Trustees do not receive remuneration. The salary of the Chief Executive is set by the Chairman of the Board of Trustees in consultation with the Finance Committee and Board of Trustees following an annual review of performance. The Charity uses Royal College of Nursing (RCN) bands, NHS pay scales and Charity Salary Surveys for benchmarking salaries of all other members of staff. Annual salary increases for staff are discussed and where applicable approved by the Finance Committee and Board of Trustees.

Research Programme: Peer Review

Given the importance of expert independent peer review in validating applications for research grants and the verification of outcomes, the Scientific Advisory Board (SAB) provides the Board of Trustees with the necessary degree of objectivity as to the quality, value for money and efficiency of research that the Charity currently funds or may consider funding. In accordance with best practice, all SAB members have been approached during the year to establish their continued willingness to serve. The SAB's Chairman, Professor Norman Maitland, has again provided essential guidance to the Board when it considered its research programme. The Board wishes to thank the SAB members for giving their time and expertise to the Charity, and to Professor Maitland, in particular, for providing advice to programme leaders in relation to their work and for his many years of service. Recruitment for a new Chair is underway following the retirement of Professor Maitland.

Internal control and risk management

Orchid is committed to active management of risk. Risk management is incorporated into governance and management structures, planning processes and all aspects of service delivery. Orchid produces a risk register which identifies risk and allocates responsibility for managing areas of risk to named individuals. The risk register identifies risks under the following headings, following Charity Commission recommendations:

- Governance and compliance
- Operational
- Financial
- Environmental / external
- Research
- Quality Assurance

Each identified risk is assessed in terms of likelihood and impact and then weighted giving a gross risk rating. Actions to minimise each risk are identified and responsibility for monitoring these is given to named individuals. The strength of each risk management strategy is given a numeric rating enabling the net risk to be calculated.

The Chief Executive is responsible to the Board for the management and implementation of the risk management strategy and reports to the Board on progress towards mitigating each risk. Risk is reviewed quarterly by staff and not less than annually by the Finance Committee and Board of Trustees. They direct the Chief Executive as to the priorities and action to be taken to mitigate or remove them.

Several other policies, therefore, deal with risk management and risk assessment e.g. Health and Safety Policy, Safeguarding etc. All policies are reviewed regularly and updated in line with changes in legislation, regulation and best practice. New policies are introduced as required.

Specific risks which, if materialised, would have had a significant impact on the Charity have been identified as:

Governance and compliance: Ability to maintain a Board of Trustees with all the skills required to ensure that all aspects of governance are adhered to.

Mitigation

- An ongoing review of the composition of the Board of Trustees to ensure that all key functions, including medical, legal and financial, are covered by suitably qualified professionals
- Training and support for Board of Trustees and Finance Committee
- Dedicated specialist resource applied in key areas e.g. health and safety, HR and legal
- Ensuring that key management personnel and advisers are of a calibre to ensure that the Charity is aware of and compliant with regulatory and similar requirements

Operational: Attracting, developing and retaining talented staff in a competitive employment market

ORCHID CANCER APPEAL

REPORT OF THE TRUSTEES

for the year ended 30 September 2019

Mitigation

- Annual salary review to include benchmarking of compensation and benefits
- Staff development, training and succession planning programmes
- Communication programme to ensure staff are involved in the development of and progress towards Orchid's Way Ahead 2017-2020 strategy and annual workplan

Financial: Economic pressures, competition, fundraising regulatory environment and consumer behaviour changes leading to a significant fall in income

Mitigation

- Annual budgeting and ongoing management, reporting and monitoring of financial performance
- Diversification of income streams
- Ongoing consideration of market and consumer trends and regulations including GDPR

Environmental / External: Changes in government policy or budgets, Charity sector regulations, or reform of the NHS or changes to the research environment that negatively impact on Orchid's work

Mitigation

- Key personnel monitor public policy and the regulatory environment on an ongoing basis to ensure potential risks can be proactively managed
- Chief Executive and Nurse Specialists attend key events and forums to help shape agenda
- Chief Executive and the Board of Trustees routinely scrutinise alignment with, and progress of, Orchid's strategy

Research: Orchid's Research Programme fails to deliver results

Mitigation

- Scrutiny and approval of research funding applications by an expert committee, Orchid Scientific Advisory Board
- Annual review of progress

Quality Assurance: Patients, their families, health and social professionals, educators and other interested parties given inaccurate, poor quality information leading to reputational damage

Mitigation

- Services developed, delivered and evaluated in line with agreed protocol and standards
- Nurse Specialists are members of the Royal College of Nursing (RCN)
- All information materials and content regularly reviewed and updated
- High-quality training for staff

TARGETS AND PROGRESS

In 2017 Orchid launched its three year strategy, "*The Way Ahead 2017-2020*". Our aim is to offer the best possible care and support for men and their families through awareness and education programmes, to promote better understanding of the signs and symptoms of these cancers, to encourage an early diagnosis and improved outcomes and to ensure the best possible care through our influence at a local and national level. Through funding world class research, our aim is to improve our understanding of male cancers, how they work, possible causes and to identify new treatments and enhance care. Support and information through our Nurse-led services enables people interested in or affected by male cancers to have the best possible outcome.

The following targets were identified for 2018-2019 and thanks to our supporters, staff, research teams, volunteers and partners we are pleased to report progress in each of these areas:

We will be the UK's leading provider of specialist support, information and inspiration for people affected by, at risk of or interested in, male specific cancers.

- *The Nurse Specialists have been responsible for developing and delivering a comprehensive information and support service for people affected by or interested in male specific cancers. They offer information and support over the telephone through the freephone National Male Cancer Helpline 0808 802 0010 and email service, the "Your Privates" testicular cancer microsite, printed and*

ORCHID CANCER APPEAL

REPORT OF THE TRUSTEES

for the year ended 30 September 2019

online information, films and videos and face-to-face at events such as health information days and Roadshows in education, community and workplace settings.

- *The Nurse Specialists and Community Engagement Team responded to 3,110 direct enquires by phone, email and face-to-face. This was an increase of 13% on the previous year reflecting increased interventions in the community and talks and presentations within community networks and workplaces. A total of 25,214 individuals accessed information about male cancer which was an increase of 11% on the previous year.*
- *Reaching deprived and hard-to-reach communities remains a priority for the Charity. Research has shown that more deprived groups have a particularly low awareness of risk factors, signs and symptoms of cancer. Orchid Nurse Specialists together with the Community Engagement Team and volunteers ran 152 Male Cancer Awareness Roadshows, Information and Training days and awareness events in community centres, public spaces, shopping centres, healthcare settings and workplaces across the UK. These events included dedicated support and training for health, social and education professionals.*
- *During the year the Charity worked with health and social care professionals, service providers, educators, MPs and Parliamentarians, other cancer charities and community groups to ensure that people affected by or interested in male cancer were offered the opportunity to “learn” about the charity, our services and contribute to improving the outlook for men affected by or at risk of male specific cancers.*
- *The “Your Privates” testicular cancer microsite continues to attract interest from health and social care professionals, educators, patients and young people. Building on this success and with input from a working group of experts including students, parents, School Nurses and educators, new resources have been developed as part of the Young Person’s Testicular Cancer Project. These will formally launch in 2020.*
- *Study Days and training events for health and social care professionals were held during the year. Highlights include:*
 - *“An Introduction to Testicular and Penile Cancer” Study Day in partnership with the British Association of Urology Nurses (BAUN) and kindly funded by a grant from the Burdett Trust for Nursing.*
 - *A series of dedicated Penile Cancer Support Meetings bringing together patients, their partners and healthcare professionals to share information, latest news and developments and much needed support. These events included presentations from those living with the disease. These events were kindly supported by a grant from Big Lottery - Awards for All.*
 - *A session at Manchester University for 30 Physician Assistants on male specific cancers. The session included current issues such as early diagnosis, support and the cancer journey. Physician Assistants are trained to work with GPs and allied healthcare professionals to diagnose and manage a range of complex diseases.*
 - *Orchid supported the UK Oncology Forum providing information and resources to over 350 delegates. The Forum is held post the ASCO (American Society Clinical Oncology) Annual Meeting thereby offering the opportunity to share vital information, treatment updates, research developments and insights from the meeting.*
 - *Orchid’s Chief Executive co-hosted a session on advanced cancer at the annual “Britain Against Cancer” conference. The session covered the challenge of being diagnosed and living with advanced cancer, the needs of those with the disease and opportunities to improve the cancer journey and patient experience. “Britain Against Cancer” is one of the largest annual cancer conferences in the UK and is attended by NHS professionals, patients, Parliamentarians, policy experts and social care professionals.*
 - *Orchid’s Chief Executive presented “A Cancer Survivor’s Perspective” at the “Improving Outcomes for People Living with and beyond Cancer” and the “Developing Effective Cancer Survivorship Services” conferences. The session covered what support people with cancer, cancer survivors and their families need and how to improve public awareness of support for people living with and beyond cancer.*

ORCHID CANCER APPEAL

REPORT OF THE TRUSTEES

for the year ended 30 September 2019

We will ensure a better quality of life for people affected by male specific cancers by helping them to make informed choices and decisions about treatment, care and support. We will empower people affected by male specific cancers by providing accurate, high quality, comprehensive information delivered in the way they want.

- *The Nurse Specialists have been responsible for developing and delivering a comprehensive information and support service for people affected by or interested in male specific cancers. They have updated the portfolio of publications, developed new film and video resources, facilitated peer to peer support opportunities and reached out to men and their families through the new Penile Cancer Support Service in Scotland.*
- *Funding was secured to develop new film and video resources for men affected by or at risk of prostate cancer - "Exploring Prostate Cancer", "Living with Advanced Stage Prostate Cancer", "Active Surveillance" and "Letter to my Unpresented Self" (part of the "Changing lives, engaging black African and black Caribbean men at risk of or with prostate cancer"). The latter launched in 2019 and has been successfully showcased at venues across the UK. Active Surveillance will launch in spring 2020.*
- *As part of our three year ambition to appoint eight Male Cancer Nurse Specialists by the end of 2020, we were pleased to appoint a further three Nurse Specialists (including recently retired Nurses) to the team. Two are based in Scotland to support the delivery of the new Penile Cancer Support Service. The team of Nurse Specialists collectively offer much needed support and information to those affected by or interested in male cancers.*
- *The Nurse Specialists continued to support men and their families through peer support programmes. These offer the opportunity to share experiences, skills and offer practical advice in a safe and supportive environment. Highlights include the Testicular Cancer Support Group at Barts Hospital.*
- *The Nurse Specialists provided face-to-face and online opportunities for men and their families affected by penile cancer to share experiences and offer support. In addition to a series of dedicated Penile Cancer Support Meetings bringing together patients, their partners and healthcare professionals, they have also supported events with the Penile Cancer Supra-networks.*
- *People affected by male specific cancers remain at the heart of what we do and the decisions we make. During the year we welcomed new members to our Editorial Board to ensure the information needs of a wide audience are met and they are able to make informed choices and decisions regarding their treatment, management options, palliative and end of life care, clinical trials, health and well-being.*

Increase investment in research. Orchid will make a significant investment in research to improve our understanding of male specific cancers and to identify new ways to treat and manage these diseases.

- *Orchid is dedicated to supporting men affected by male cancer through a programme of high quality research. Advised by the Scientific Advisory Board (SAB), we fund research which helps improve our understanding of male cancer and works towards improving treatment and management techniques for patients. Priority areas include supporting the Orchid Research Tissue Bank, research into rare cancers, diagnostics and encouraging young researchers into the field of male cancer through training and career development awards including Study and Travel Awards.*
- *Orchid was pleased to offer grant extensions to Professor Lu's study "Using circulating tumour cells for prostate cancer diagnosis and monitoring disease progression and treatment response" and to Professor Berney's "The Orchid Research Tissue Bank: a bespoke trials-orientated tissue bank for investigation of prostate, testis and penile cancer". A new grant round is expected to open in 2020-2021.*
- *Through media campaigns, attendance at conferences, training events for health professionals, meetings and information days, the Charity continued to increase awareness of research progress and male cancer.*

ORCHID CANCER APPEAL

REPORT OF THE TRUSTEES

for the year ended 30 September 2019

Early diagnosis can improve survival. We will raise awareness of male specific cancers, the signs and symptoms, promote self-checks and encourage an early diagnosis.

- *During the year Orchid's work and campaigns continued to attract media coverage and helped to raise awareness of male cancer.*
- *"Manversation: the campaign for prostate cancer conversations" aims to raise awareness of the symptoms of advanced prostate cancer, encouraging men to speak up about potential new symptoms as soon as they experience them. The campaign includes information materials for healthcare professionals, family members and men with advanced prostate cancer, a video and web based materials. During the year a new campaign was launched aimed at engaging younger audiences and encouraging conversations and early interventions. The campaign included a series of Facebook ads, Google Display and Google Ad Words.*
- *The annual Orchid Male Cancer Awareness Week took place from the 2-9 September 2019. The campaign focussed on male specific cancers and in particular prostate cancer. Campaign highlights include:*
 - *The Charity commissioned independent research into GP's understanding and thoughts on key areas including risk factors, the PSA test, treatments, support during the cancer journey and advanced prostate cancer. Over 100 UK GPs took part in the survey and the outcomes were launched during the Week.*
 - *In response to the survey results, the 'F.A.C.E. up to prostate cancer' campaign was promoted to encourage GPs and men to think about and be aware of four key risk factors associated with the development of prostate cancer. Campaign activities included the 'F.A.C.E. up to prostate cancer' infographic and poster, consumer and trade media drives, social media content and website content.*
 - *Orchid's Male Cancer Awareness Roadshows were held in Carlisle, Scarborough and Grimsby.*

The Week was the most successful campaign to date with over 790,000,000 OTS (Opportunities to See). The Week generated over 57 pieces of coverage including eight national newspaper articles including The Daily Telegraph, Daily Mail, and The Sun and 40 pieces of news website coverage. We were delighted that 21 Members of Parliament and 13 regional MPs shared the Week and the 'F.A.C.E up to prostate cancer' risk factor awareness campaign on Twitter together with the NHS, Scottish government, Clinical Commissioning Groups, local councils and charities. The 'F.A.C.E. up to prostate cancer' campaign was the winner of the Pharmaceutical Market Excellence Awards 2018 (PMEA 2018) in the category of 'Excellence in Engagement through Multiple Channels'.

- *Reaching deprived and hard-to-reach communities remains a priority for the Charity. Research has shown that more deprived groups have a particularly low awareness of risk factors, signs and symptoms of cancer. Orchid Nurse Specialists together with the Community Engagement Team and volunteers ran 152 Male Cancer Awareness Roadshows, Information and Training days and awareness events in community centres, public spaces, shopping centres, healthcare settings and workplaces across the UK. These events included dedicated support and training for health, social and education professionals.*
- *The Big Lottery Fund – Reaching Communities Programme awarded a three grant of £377,802 towards the project "Changing Lives – engaging black African and Caribbean men at risk of or affected by prostate cancer". Working with the Charity Cancer Black Care, the grant enables Orchid to develop new services and reach black African and black Caribbean men and disadvantaged communities affected by or at risk of prostate cancer across seven London boroughs. The programme launched in January 2017 and has seen the delivery of community based events, Roadshows, awareness activities, support groups, new partnerships and collaborations and information resources. Highlights during the year include the "One in Four" photographic project supported by Healthwatch Brent and leading photographer Paul Vickery. The exhibition launched in May at the Brent Civic Centre in London and ran until September. It was officially opened by the newly appointed Mayor of Brent, Cllr Ernest Ezeajughi, and Leader of Brent Council Muhammed Butt. Over 60 people, including prostate cancer patients and their families, representatives from Brent Council, Clinical Commissioning Groups, Public Health England and local cancer support services including Cancer*

ORCHID CANCER APPEAL

REPORT OF THE TRUSTEES

for the year ended 30 September 2019

Black Care attended the launch. A new video training tool – “Letter to my unrepresented self” was developed and launched to assist healthcare professionals to better support black African and black Caribbean men affected by or at risk of prostate cancer. The film features the experience of a young man diagnosed with prostate cancer. It premiered in London at a Reception which saw over 70 cancer patients and their families, specialist Nurses, Cancer Commissioning Leads and representatives from partner charities coming together. Building on this success a new film and awareness resources are in development.

To be the voice for people affected by male specific cancers and to reduce inequalities associated with rare cancers.

- *Orchid is committed to collaborating with health and social care professionals and other representative groups to raise awareness of rare cancers and campaign for better care. During the year the Charity worked with a range of organisations including Macmillan Cancer Support, Cancer Research UK, The Urology Foundation, British Association of Urology Nurses (BAUN), Movember, Prostate Cancer UK, Tackle Prostate Cancer and with specialist teams such as Penile Cancer Supra-networks. Orchid is an active member of the Testicular Cancer Network and Cancer52, an alliance of over 80 organisations working to address the inequalities that exist in policy, services and research into the less common cancers. Orchid’s Chief Executive is on the Board of Cancer52 and interim Chair of the Testicular Cancer Network.*
- *Orchid presented and exhibited at the “Britain Against Cancer” conference hosted by the All Party Parliamentary Group on Cancer (APPGC). This conference is one of the largest and most influential annual cancer events in the UK and is attended by NHS professionals, patients, Parliamentarians, policy experts and social care professionals. The conference is an excellent opportunity to meet the cancer community as well as hear from and question key decision makers in the NHS and government.*
- *Orchid continues to raise awareness of rare cancers and ensure those affected receive the same level of care and support as those affected by more common cancers. Alongside information resources, Study Days and training events for health and social care professionals were held during the year. Highlights include:*
 - *“An Introduction to Testicular and Penile Cancer” Study Day in partnership with the British Association of Urology Nurses (BAUN) and kindly funded by a grant from the Burdett Trust for Nursing.*
 - *A series of dedicated Penile Cancer Support Meetings bringing together patients, their partners and healthcare professionals. These events included presentations from those living with the disease. These events were kindly supported by a grant from Big Lottery - Awards for All.*
 - *A session at Manchester University for 30 Physician Assistants on male specific cancers. The session included current issues such as early diagnosis, support and the cancer journey. Physician Assistants are trained to work with GPs and allied healthcare professionals to diagnose and manage a range of complex diseases.*
 - *Orchid supported the UK Oncology Forum providing information and resources to over 350 delegates. The Forum is held post the ASCO (American Society Clinical Oncology) Annual Meeting thereby offering the opportunity to share vital information, treatment updates, research developments and insights from the meeting.*
 - *Orchid’s Chief Executive co-hosted a session on advanced cancer at the annual “Britain Against Cancer” conference. The session covered the challenge of being diagnosed and living with advanced cancer, the needs of those with advanced cancer and how to improve the cancer journey. “Britain Against Cancer” is one of the largest annual cancer conferences in the UK and is attended by NHS professionals, patients, Parliamentarians, policy experts and social care professionals.*

ORCHID CANCER APPEAL

REPORT OF THE TRUSTEES

for the year ended 30 September 2019

- *Orchid's Chief Executive presented "A Cancer Survivor's Perspective" at the "Improving Outcomes for People Living with and beyond Cancer" and the "Developing Effective Cancer Survivorship Services" conferences. The session covered what support people with cancer, cancer survivors and their families need and how to improve public awareness of support for people living with and beyond cancer.*
- *Orchid Nurses continued to support men and their families through peer support programmes. These offer the opportunity to share experiences, skills and offer practical advice in a safe and supportive environment. Highlights include the Testicular Cancer Support Group at Barts Hospital.*
- *We are committed to supporting men affected by penile cancer and to working with patients and carers, supra-networks and Penile Cancer Teams to develop networking opportunities. During the year Nurse Specialists provided face-to-face and online opportunities for men and their families to share experiences and offer support.*
- *People affected by male specific cancers remain at the heart of what we do and the decisions we make. During the year we welcomed new members to our Editorial Board to ensure the information needs of a wide audience are met and they are able to make informed choices and decisions regarding their treatment, management options, palliative and end of life care, clinical trials, health and well-being.*

Improving care and outcomes. We will work in partnership with cancer charities, health and social care professionals, educators, policy makers and the Department of Health and NHS (England, Scotland, Wales and Northern Ireland) to improve care and deliver the best possible, integrated service for men and their families.

- *Orchid has taken an active role in supporting Parliamentarians, Ministers and policy makers to raise the profile of male cancers and influence opinion and policy development. In October 2018 the Charity held the 'Male Cancer in Parliament' Reception at the House of Commons. Over 80 guests including clinicians, researchers, charity representatives and patients groups attended the event and learnt about the work of Orchid and the need to raise awareness of male cancers. The Charity was delighted to welcome Sharon Hodgson MP and Shadow Minister for Cancer Strategy who spoke about the need to raise awareness of male cancer.*
- *The All Party Parliamentary Group (APPG) on Male Cancer formally launched in 2019. The APPG on Male Cancer brings together the experience and expertise of clinicians, researchers, patients, carers and charities to take male cancer to the heart of Westminster. Orchid provides the Secretariat.*
- *The 'Should We Now Be Screening for Prostate Cancer?' Reception took place at the House of Commons in February. This was a joint event supported by CHAPS, Tackle Prostate Cancer and Orchid. Over 100 people including clinicians, researchers, charity representatives and patients groups, attended the event which was an opportunity to learn more about the issues around screening for prostate cancer. Speakers included James Cleverly MP, Professor Dr Monique Roobol from the Netherlands, Lord Riberio, Sir Bernard Jenkins MP and Professor Sir Mike Richards.*
- *Orchid is an active member of the Advanced Cancers Coalition (ACC). The Coalition aims to identify and address key issues for patients with advanced cancer and to drive improved care and outcomes. The ACC includes representatives from skin, lung, ovarian and brain cancers. The Group is supported by Roche UK.*
- *Orchid presented and exhibited at the "Britain Against Cancer" conference hosted by the All Party Parliamentary Group on Cancer (APPGC). This conference is one of the largest and most influential annual cancer events in the UK and is attended by NHS professionals, patients, Parliamentarians, policy experts and social care professionals. The conference is an excellent opportunity to meet the cancer community as well as hear from and question key decision makers in the NHS and government.*
- *Orchid is committed to collaborating with health and social care professionals and other representative groups to raise awareness of rare cancers and campaign for better care. During the year the Charity worked with a range of organisations including Macmillan Cancer Support, Cancer Research UK, The Urology Foundation, British Association of Urology Nurses (BAUN), Movember, Prostate Cancer UK, Tackle Prostate Cancer and with specialist teams such as Penile Cancer Supra-*

ORCHID CANCER APPEAL

REPORT OF THE TRUSTEES

for the year ended 30 September 2019

networks. Orchid is an active member of the Testicular Cancer Network and Cancer52, an alliance of over 80 organisations working to address the inequalities that exist in policy, services and research into the less common cancers. Orchid's Chief Executive is on the Board of Cancer52 and interim Chair of the Testicular Cancer Network.

- *The Big Lottery Fund – Reaching Communities Programme awarded a three grant of £377,802 towards the project “Changing Lives – engaging black African and Caribbean men at risk of or affected by prostate cancer”. Working with the Charity Cancer Black Care, the grant enables Orchid to develop new services and reach black African and black Caribbean men and disadvantaged communities affected by or at risk of prostate cancer across seven London boroughs. The programme launched in January 2017 and has seen the delivery of community based events, Roadshows, awareness activities, support groups, new partnerships and collaborations and information resources. Highlights during the year include the “One in Four” photographic project supported by Healthwatch Brent and leading photographer Paul Vickery. The exhibition launched in May at the Brent Civic Centre in London and ran until September. It was officially opened by the newly appointed Mayor of Brent, Cllr Ernest Ezeajughi, and Leader of Brent Council Muhammed Butt. Over 60 people, including prostate cancer patients and their families, representatives from Brent Council, Clinical Commissioning Groups, Public Health England and local cancer support services including Cancer Black Care attended the launch. A new video training tool – “Letter to my unrepresented self” was developed and launched to assist healthcare professionals to better support black African and black Caribbean men affected by or at risk of prostate cancer. The film features the experience of a young man diagnosed with prostate cancer. It premiered in London at a Reception which saw over 70 cancer patients and their families, specialist Nurses, Cancer Commissioning Leads and representatives from partner charities coming together. Building on this success a new film and awareness resources are in development.*

Transforming Orchid. We will have the internal structure, capabilities and resources to enable us to meet our objectives.

- *Trustees have acknowledged the excellent progress that has been made towards Orchid's strategy “The Way Ahead 2017-2020”, the importance of collaborations with other charities and the work undertaken with Parliamentarians, Ministers and policy makers to raise the profile of male cancers and influence opinion and policy development. There is an opportunity to build on these areas going forward and to further develop the current research programme with a focus on “innovation”.*
- *Key to the success of the Charity is the significant contribution made by staff, specialist consultants and volunteers. The Charity welcomed new staff during the year: three Nurse Specialists (including recently retired Nurses), a Prostate Cancer Project Administrator and Events Manager to help drive the strategy forward.*
- *Orchid is committed to the management, training and personal development of its staff and volunteers. Staff have attended training courses throughout the year and joined relevant professional bodies such as the Institute of Fundraising as part of their ongoing professional development.*

Research

Orchid-funded research has once again made significant strides in the past year. The 16th Annual Report reflected a general opinion that much progressive work had been carried out across all areas. The following is a summary of the key achievements:

Professor Daniel Berney Barts Cancer Institute, Barts & The London School of Medicine, QMUL

The Orchid Research Tissue Bank is led by Professor Berney, one of the world's leading genito-urinary pathologists. The Orchid Research Tissue Bank carries out translational work which aims to link molecular and pathological data with clinical trials. The aim of the team is to curate a bespoke tissue bank concentrating on the three male cancers. In summary, it:

- holds over 9000 male-specific cancer tissue samples to facilitate understanding of prostate, testicular and penile cancers, from the potential causes, through to how they are diagnosed, treated and possibly prevented

ORCHID CANCER APPEAL

REPORT OF THE TRUSTEES

for the year ended 30 September 2019

- houses one of the largest collections of penile cancer tissues in Europe, one of the largest testicular tissue banks in the world and is custodian of the largest series of untreated prostate cancers globally
- collaborates with research on an international scale, as well as conducting its own pathological and molecular research into penile, prostate and testicular cancer
- works in collaboration with other Orchid funded research projects
- is committed to the ethical collection, processing and storage of samples. Another five year extension to the ethics for the tissue bank in addition approval for pre-screening of patients for consent under Section 251 from Confidentiality Advisory Group (CAG) has been requested. The initial feedback received are positive. Waiting for final outcome letter.
- has major external collaborations with prestigious research bodies such as The Institute of Cancer Research, UCL, Memorial Sloan Kettering Hospital and Indiana University Hospital, The Cleveland Clinic and the Karolinska Institute
- is a valuable source of information for students and specialist researchers wanting to learn more about male cancers; as well as being accessible to lay visitors
- Focuses on samples where outcome data is available from clinical trials. Advances in technology increasingly allow high quality sequencing and molecular work in these media.

Progress October 18-Sept 19

- Prostate cancer: Our group, which has until now concentrated on early prostate cancer is developing more collections of late prostate cancer. Continuing with this theme, over 500 cases have been received and processed for STAMPEDE clinical trial. Histopathology reviews are carried out in association between Professor Berney and the PhD student who is a histopathologist herself for these cases. In addition over 400 patient samples have been stained for Ki67.

Further work continues to be published from the trans-atlantic prostate cohort into early stage disease. Together with the international work we now have a unique suite of samples for use nationally and internationally. Collaboration in UK and international projects is reflected in the publications below. Collaboration for PROVENT is ongoing. Have received samples for 101 patients. These have been sectioned and couriered to Myriad for analyses.

- Testis cancer: Collection of drug resistant cases from previous clinical trials in collaboration between MRC CTU is now complete. PhD collaboration of Dr Thomas Wagner Neilsen in University of Copenhagen is continuing successfully.
- Penile cancer: The team's work focusses on the genetics of penile cancer and trying to understand the key drivers to spread in HPV (human papilloma virus) positive and negative tumours. Continue to receive tissue samples from St George's hospital in collaboration with Mr Nick Watkin. Collection of material from international penile chemotherapy studies is ongoing
- Publications: Since March 2015 Professor Berney has appeared in 50 publications, covering a vast range of topics and 12 peer-reviewed publications Oct16-Sept 17. His work has now been cited by other peer review papers over 8000 times and he has an H index of 47. (47 papers cited more than 47 times)
- Collection of tissue: Continued collection of tissue has enabled the Tissue Bank team to hold novel collections of all three cancer types, enabling research and increasing its ability to collaborate with other groups.

ORCHID CANCER APPEAL

REPORT OF THE TRUSTEES

for the year ended 30 September 2019

Professor Yong-Jie Lu
Centre for Molecular Oncology,
Barts Cancer Institute, Barts & The London School of Medicine, QMUL

Prostate cancer is the most common cancer in Western men and recently prostate cancer caused deaths have overtaken breast cancer in the UK. Current diagnosis of human cancer is based on pathological examination of tissue biopsy samples, which is a very invasive procedure with serious modality. Therefore, it cannot be used frequently for monitoring cancer development, progression and response to treatment. Blood samples can however be easily taken from patients and can be used for monitoring cancer development and progression if materials representing tumour status can be identified. Biomarkers in the blood circulation have been investigated for decades and the best example of using blood proteins to detect and monitor cancer is the PSA for prostate cancer. Routine PSA indeed helps with early diagnosis. However, as it is unspecific, PSA screening also leads to large numbers of patients undergoing unnecessary invasive biopsy procedure and therefore is a great burden to clinical experts. Professor Lu's team is currently focusing on developing cancer specific biomarkers in the blood sample, including circulating tumour cells (CTCs), cancer cell secreted extracellular bodies called exosome and platelets, which are very rich in the blood to produce clotting when it is necessary. CTCs are the route for cancer spread in the body, called metastasis, which is the main cause of cancer death. Cancer cells also secrete exosomes to enable cancer cells to establish the body environment for them to grow and escape immune system attack. Platelets, although not coming from cancer cells, interact with cancer cells and play an important role in cancer development and programme. The team planned to investigate the potential to use CTCs, exosomes and platelets for cancer detection (thereby avoiding unnecessary tissue biopsy), prognosis and disease treatment response monitoring. These will provide a diagnostic basis that enables personalized cancer patient treatment.

Most cancer patients die of metastasis cancer. Based on the team's previous work and expertise in cancer genetics and cancer metastasis, as well as the link of finding blood cancer exosome with cancer metastasis, Professor Lu and his team have also investigated further the molecular/genetic mechanisms of prostate cancer, in particular cancer metastasis.

The specific objectives were:

- Prostate cancer CTC study in order to predict and monitor cancer progression and therapeutic responses using blood tests.
- Prostate cancer CTC study in order to identify which patients with a risk of prostate cancer need tissue biopsy to confirm that they have cancer.
- Evaluating the potential of using blood platelet study for early prostate cancer detection and identifying which patients with a risk of prostate cancer need tissue biopsy to confirm that they have cancer.
- Prostate cancer exosome study in order to detect the development of metastasis hormone resistance cancer and understand the molecular mechanism for the development of novel forms of therapies.
- Participate in the international prostate cancer genetic risk and cancer genome consortium to understand the genetic and molecular mechanisms for prostate cancer development.

Linked to the above objectives, Professor Lu and his team have achieved the following research progress:

- By comparing CTCs detected or not in hundreds of newly diagnosed prostate cancer patients, they found that CTC analysis can help to distinguish indolent and aggressive cancers.
- By analysing > 100 pre-diagnostic biopsy patients' blood samples with suspected prostate cancer, they established the diagnostic value of CTCs in combination with PSA.
- The data from the above studies has been published on the top urology journal, Journal of Urology, which is the official journal of America Urology Association and attracted news release in dozens of national and international media, including BBC Radio 4.
- Additional CTC analysis has been performed on prostate cancer patients under chemotherapy during this period, each with blood samples before, during and after a specific drug treatment to correlate with outcome. Data analysis showed the potential of using CTC status to predict patient response to chemotherapy.
- Following the identification of the correlation of several miRNAs, a type of genetic material that regulate gene production level, in blood exosomes with prostate cancer hormone therapy failure in the

ORCHID CANCER APPEAL

REPORT OF THE TRUSTEES

for the year ended 30 September 2019

previous year, the team confirmed the top differentially present miRNA in more patient samples both from Barts Hospital and the Mayo Clinic in the USA.

- In cultured cell, they found that this miRNA increases prostate cancer cell metastasis ability.
- The team identified a panel of miRNAs differentially present in prostate cancer patients and non-cancer individuals, suggesting the potential in improving cancer early detection and avoiding unnecessary biopsy.
- Together with the Orchid Research Tissue Bank, the team have collected more than 500 prostate cancer patient blood samples, isolated CTCs and other blood component for future cancer biomarker study.
- On testicular tumour, together with Dr. Jonathan Shamash and Professor Daniel Berney, they tested an antibody drug in cultured cell lines and cancer tissue samples for its potential in improve the treatment of chemotherapy resistant cancer. The study was published in the American Journal of Cancer Research.
- Publication summary: Contributed to dozens of peer-reviewed original research publications, including more than 20 submitted to Nature (five papers) and Nature sister journals during this funding period and formally published in February 2020 as the joint effort of the Pan-cancer International Cancer Genome Consortium. Published three book chapters.
- Analysed CTCs in 300 blood samples from prostate cancer in the past year.

Fundraising

Incoming resources for year totalled £846,169 against the previous year total of £798,752. There has been strong performance across all areas reflecting new activities and donations from a wide range of supporters. A number of grants which were expected during the year have since been received in the following year.

The following information summarises the various disciplines:

Donations & Legacies. Income from general donations and legacies totalled £650,135.

Business Community. Income from the business community totalled £120,076 and reflects the generous support of a range of companies including Paperchase, NEXT, Bayer plc, Sanofi, Janssen UK, Roche UK, Las Iguanas, LGV Training Company and the ICAP Charity Day auction. The Charity was delighted to be the recipient of the BGC Charity Day 2018 which generated significant funds. A new partnership with payroll giving agency, Hands on Payroll Giving has launched and is generating an important source of revenue and new, long term supporters for the Charity.

Grants: Trusts and Foundations

Income from a range of both small and large trusts and foundations totalled £161,065 and included grants towards research, community based projects, education and the Nurse-led Support Services. We are grateful to the Big Lottery Fund - Reaching Communities Programme and Awards for All for their support.

Events. It has once again been a busy year for the Orchid's events programme. Income from events totalled £312,526. Events income was the result of several key events during the year including the Virgin Money London Marathon, overseas Marathons, Broadgate Tower Abseil, the annual Orchid River Run and The Great Willy Waddle. Events organised by supporters include the 10th annual Twyford Beer Festival, The Orchid Winchester Ball, golf days, quiz nights, cycle rides and running events. The Charity is indebted to the many supporters, friends and volunteers who work tirelessly to raise funds and awareness of male cancer.

In recent years, the reputation of the charity sector has been adversely affected and there is an urgent need to rebuild trust and confidence with the public. Orchid recognises the importance of listening to and putting supporters at the centre of everything that we do. In taking this approach, we are registered with the Fundraising Regulator and adhere to the code of fundraising when carrying out our activities. Our staff are committed to following codes of good practice and standards developed by the fundraising community through the work of the Institute of Fundraising (IoF) and other professional bodies. The Charity operates a clear and stringent complaints handling procedure that is reported to the Senior Management team and the Board of

ORCHID CANCER APPEAL

REPORT OF THE TRUSTEES

for the year ended 30 September 2019

Trustees. As part of our supporter care programme, we have agreed policies and procedures in place and written agreements with external agencies that we engage to help us or who raise funds for the Charity. We ensure that anyone engaged to work for us is trained in and respects our aims and objectives and carries out their activities with the same high standards and care we would ourselves. During the year we received less than five complaints in relation to our fundraising activities. We remain committed to improving our practice, learning from supporter feedback.

FINANCIAL REVIEW

Investment Policy

The Trustee's policy is to hold funds on both short and long term deposits with a variety of banks.

Results for the Year

Income for the year ended 30 September 2019 totalled £846,169 (2018: £798,752). After total expenditure of £918,939 (2018: £1,218,462), the year's activities show a net deficit of £72,770 (2018: deficit of £419,710). Total reserves at the end of the year amounted to £938,402 (2018: £1,011,172).

Reserves Policy

Designated reserves are funds that have been earmarked by the Trustees for future expenditure on the objectives of the Charity, and at the end of the year the Trustees had designated £166,157 towards future research grant awards. In addition £121,808 has been designated to help fund the costs of increased organisational capacity with the Charity and a further £83,658 designated to help fund specific awareness activities.

Free reserves are distinct from funds that have been earmarked or 'designated' for future expenditure on the objectives of the Charity, but for which legal liability has not yet been accepted. They must be maintained at a level which ensure the Charity's core activity of funding research and awareness during a period of sustained unforeseen difficulty and a proportion must be in a readily realisable form. The calculation of the required level of reserves is an integral part of the Charity's planning, budgeting and forecast cycle. It should take into account:

- risks associated with each income and expenditure stream differing from that budgeted
- planned activity level
- organisational commitments.

The available free reserves net of tangible fixed assets are £334,804 (2018: £303,777). It is the Charity's policy to maintain free reserves of approximately 3-4 months of operating costs. At current levels of expenditure this equates to £230,000-£310,000.

FUTURE PLANS

Building on our current success and achievements, informed by the knowledge and expertise of a range of stakeholders and taking into consideration opportunities and the external environment, the Charity has made good progress against its three year strategy "*The Way Ahead 2017-2020*". It is a bold and ambitious vision encompassing men, their partners, family members, friends, health and social care professionals, researchers, service providers, educators, policy makers, other cancer charities, our staff, Trustees, volunteers and donors. We will work towards achieving our seven priorities in the final year of the strategy to order to improve the outlook for current and future generations of men:

- We will be the UK's leading provider of specialist support, information and inspiration for people affected by, at risk of or interested in, male specific cancers.
- We will ensure a better quality of life for people affected by male specific cancers by helping them to make informed choices and decisions about treatment, care and support. We will empower people affected by male specific cancers by providing accurate, high quality, comprehensive information delivered in the way they want.
- Increase investment in research. Orchid will make a significant investment in research to improve our understanding of male specific cancers and to identify new ways to treat and manage these diseases.

ORCHID CANCER APPEAL

REPORT OF THE TRUSTEES

for the year ended 30 September 2019

- Early diagnosis can improve survival. We will raise awareness of male specific cancers, the signs and symptoms, promote self-checks and encourage an early diagnosis.
- To be the voice for people affected by male specific cancers and to reduce inequalities associated with rare cancers.
- Improving care and outcomes. We will work in partnership with cancer charities, health and social care professionals, educators, policy makers and the Department of Health and NHS (England, Scotland, Wales and Northern Ireland) to improve care and deliver the best possible, integrated service for men and their families.
- Transforming Orchid. We will have the internal structure, capabilities and resources to enable us to meet our objectives.

Post Balance Sheet Event

This financial year has been significant for both the charity and the nation. Very sadly in February 2020, our dedicated Chairman, Robert Lane passed away suddenly, after serving on the Board of Trustees so diligently for over 12 years and is deeply missed by his fellow Trustees, staff and our supporters. Orchid founder, Colin Osborne was appointed the new Chairman of the Board of Trustees.

Another key change to the Senior Leadership team was the departure of our Chief Executive, Rebecca Porta who had been in post for 9 years. Ali Orhan was appointed as our Interim Chief Executive, who has been with the charity for over 3 years. Since his appointment, he has further streamlined our structure ensuring a cost-effective means of operation, while enhancing our services and support provision.

While we want to share our plans for the forthcoming year, we do need to acknowledge how quickly and how much our world has changed since the start of 2020 and our trajectory as a charity. Covid-19 has had a significant impact on both our funding and service provision, significantly reducing and eliminating part of our face to face programme and becoming much more digitally focused. In managing our cost base, we have utilised the government furlough scheme and reduced our head count. To ensure the wellbeing of our staff we have the ability to work effectively from home as well as the office, as a result we have reduced our office space requirements and associated cost.

While much of everyday life has changed, men and families affected by a diagnosis of male cancer have not. Therefore, we will continue to help patients today, so that they can lead fulfilled lives going forward.

Orchid's Mission

To support, inform and be the voice for all those affected by male specific cancers

We will do this in 2020/2021 by: -

Information and Awareness Programme

Our renowned information and awareness programme will utilise more extensively digital platforms, broadening our reach, ensuring all our materials are readily accessible. This will not only address the changes required due to the pandemic but importantly complements people's requirements, positioning Orchid as a forward thinking charity.

We plan to roll out and share within the community our virtual programmes, producing interactive and animated presentation decks dedicated to each male cancer (testicular, prostate and penile) for those affected, while also being proactively distributed to health professionals, empowering them to support patients as required.

We will be developing an e-learning tool for businesses nationwide to complement part of their wellbeing and/or induction programmes, standardising information on the risks, symptoms and treatments of all male cancers.

When Covid-19 permits we will secure a presence within shopping centres and other private sites utilising their plasma screens promoting the signs, symptoms and risks of the male-specific cancers.

ORCHID CANCER APPEAL

REPORT OF THE TRUSTEES

for the year ended 30 September 2019

Support

We will continue to provide our much-needed support via our Freephone National Male Cancer Helpline. Due to Covid-19, the need for this is even greater. As a result, we will be extending the opening hours of the specialist nurse-led helpline, while also providing a new out of hours service.

This will be supported by our online helpline, which will continue to be refined during the course of the year, to ensure it is efficient while meeting and addressing the needs of patients.

There is no doubt that during the past six months, anxiety levels of those affected has increased, with many not feeling comfortable visiting their GP. Therefore, we will introduce virtual community support groups both online and by phone.

We will build our relationships and reach within the Devolved Countries, cementing our presence and influence within Scotland.

Research

Orchid is committed to continuing its focused programme of research. Research has always been at the core of our activity. We are exploring new ways to grow our research grants and measure the impact of this research.

Public Affairs

We will maintain our All-Party Parliamentary Group to ensure male cancer has a prominent platform within government, particularly addressing funding and patient care pathways.

Fundraising

All our activities are heavily reliant on our voluntary donations and while we continue to have committed supporters the Covid-19 impact on fundraising is material. We will adapt and enhance our approach within some of our income streams particularly grants, the National Lottery, and Charitable Trusts and Foundations as personal giving is understandably challenged. The majority of physical events in the coming year have been or will be cancelled or postponed. We will support our funders' participation in virtual events and other initiatives to replace the events revenue stream.

We will build on our individual giving programme which provides a sustainable regular income.

While we will continue to work alongside established third parties, such as The London Marathon, we will consider additional engagement opportunities, such as virtual bespoke events, while enhancing our existing own events programme.

Many Charitable Trusts and Foundations have refined their giving criteria and we will continue to apply for emergency funding, where available, with which we have had some success this year. By delivering our innovative community programme, this will aid our conversations with local funders, while building new warm partnerships.

While we acknowledge that 2020/21 will be a challenging year, with the right infrastructure and appetite to develop new initiatives, we remain confident that we will achieve our aims and ambitions.

ORCHID CANCER APPEAL

REPORT OF THE TRUSTEES

for the year ended 30 September 2019

FORMAL STATEMENTS

Statement of Trustees' Responsibilities

The Trustees, who are also directors of Orchid Cancer Appeal for the purposes of company law, are responsible for preparing the Trustees' Report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice.)

Company law requires Trustees to prepare financial statements for each financial year which give a true and fair view of the state of the affairs of the charitable company and of the incoming resources and application of resources, including the income and expenditure, of the charitable company for that period. In preparing these financial statements, the Trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in the Charities SORP;
- make judgements and estimates that are reasonable and prudent;
- state whether applicable UK Accounting Standards have been followed, subject to any material departures disclosed and explained in the financial statements;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charitable company will continue in business.

The Trustees are responsible for keeping proper accounting records that disclose with reasonable accuracy at any time the financial position of the charitable company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the charitable company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

The Trustees are responsible for the maintenance and integrity of the Charity and financial information included on the Charity's website. Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

Auditor's Information

So far as each of the directors at the time the Trustees' report is approved is aware:

- a) there is no relevant information of which the auditors are unaware; and
- b) they have taken all relevant steps they ought to have taken to make themselves aware of any relevant audit information and to establish that the auditors are aware of that information.

The auditor, Moore Kingston Smith LLP, has been authorised for appointment in accordance with Section 485 of the Companies Act 2006.

Moore Kingston Smith LLP has indicated its willingness to continue in office and in accordance with the provisions of the Companies Act, it is proposed that it will be re-appointed auditor for the ensuing year.

The financial statements have been prepared in accordance with the provisions of the Companies Act 2006 Part 15 relating to small companies, the Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (The FRS 102 Charities SORP) and the Memorandum and Articles of Association of the Company.

Signed on behalf of the Trustees.



C S Osborne
Chairman of Trustees
Date: 22 September 2020

ORCHID CANCER APPEAL

INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF ORCHID CANCER APPEAL

For the year ended 30 September 2019

Opinion

We have audited the financial statements of Orchid Cancer Appeal ('the company') for the year ended 30 September 2019 which comprise the Statement of Financial Activities, the Balance Sheet, the Cash Flow Statement and notes to the financial statements, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including FRS 102 'The Financial Reporting Standard Applicable in the UK and Ireland' (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:

- give a true and fair view of the state of the charitable company's affairs as at 30 September 2019 and of its incoming resources and application of resources, including its income and expenditure, for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- have been prepared in accordance with the requirements of the Companies Act 2006.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs(UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor's Responsibilities for the audit of financial statements section of our report. We are independent of the charitable company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

We have nothing to report in respect of the following matters in relation to which the ISAs (UK) require us to report to you where:

- the trustees' use of the going concern basis of accounting in the preparation of the financial statements is not appropriate; or
- the trustees have not disclosed in the financial statements any identified material uncertainties that may cast significant doubt about the company's ability to continue to adopt the going concern basis of accounting for a period of at least twelve months from the date when the financial statements are authorised for issue.

Other information

The other information comprises the information included in the annual report, other than the financial statements and our auditor's report thereon. The trustees are responsible for the other information. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether there is a material misstatement in the financial statements or a material misstatement of the other information. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

ORCHID CANCER APPEAL

INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF ORCHID CANCER APPEAL

For the year ended 30 September 2019

We have nothing to report in this regard.

Opinions on other matters prescribed by the Companies Act 2006

In our opinion, based on the work undertaken in the course of the audit:

- the information given in the trustees' annual report for the financial year for which the financial statements are prepared is consistent with the financial statements; and
- the trustees' annual report has been prepared in accordance with applicable legal requirements.

Matters on which we are required to report by exception

In the light of the knowledge and understanding of the company and its environment obtained in the course of the audit, we have not identified material misstatements in the trustees' annual report.

We have nothing to report in respect of the following matters where the Companies Act 2006 requires us to report to you if, in our opinion:

- adequate accounting records have not been kept, or returns adequate for our audit have not been received from branches not visited by us; or
- the financial statements are not in agreement with the accounting records and returns; or
- certain disclosures of trustees' remuneration specified by law are not made; or
- we have not received all the information and explanations we require for our audit, or
- the trustees were not entitled to prepare the financial statements in accordance with the small companies regime and take advantage of the small companies exemption in preparing the Strategic Report.

Responsibilities of trustees

As explained more fully in the trustees' responsibilities statement set out on page 19, the trustees (who are also the directors of the charitable company for the purposes of company law) are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the trustees are responsible for assessing the charitable company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the trustees either intend to liquidate the charitable company or to cease operations, or have no realistic alternative but to do so.

Auditor's responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with ISAs (UK) we exercise professional judgement and maintain professional scepticism throughout the audit. We also:

ORCHID CANCER APPEAL

INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF ORCHID CANCER APPEAL

For the year ended 30 September 2019

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purposes of expressing an opinion on the effectiveness of the charitable company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the trustees.
- Conclude on the appropriateness of the trustees' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the charitable company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the charitable company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

Use of this report

This report is made solely to the charitable company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the company's members those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to any party other than the charitable company and charitable company's members as a body, for our audit work, for this report, or for the opinions we have formed.

Moore Kingston Smith LLP.

James Saunders FCCA DChA
for and on behalf of Moore Kingston Smith LLP, Statutory Auditor

Date: 23 September 2020

Devonshire House
60 Goswell Road
London
EC1M 7AD

ORCHID CANCER APPEAL

STATEMENT OF FINANCIAL ACTIVITIES *(incorporating an income and expenditure account)*

For the year ended 30 September 2019

	Note	Unrestricted £	Restricted £	Year ended 30 September 2019 £	Restated Year ended 30 September 2018 £
Income from:					
Donations & Legacies	2	469,620	180,515	650,135	664,110
Charitable Activities	4	-	185,526	185,526	121,133
Trading Activities		527	-	527	1,039
Investments		9,981	-	9,981	12,470
Total income		480,128	366,041	846,169	798,752
Expenditure on:					
Raising funds					
Fundraising (donations & grants)	5	247,885	-	247,885	369,568
Charitable Activities					
Education & Awareness	5	247,314	347,045	594,359	614,320
Research	5	37,745	38,950	76,695	234,574
Total expenditure		532,944	385,995	918,939	1,218,462
Net income / (expenditure) and net movement in funds	8	(52,816)	(19,954)	(72,770)	(419,710)
Reconciliation of funds					
Total funds brought forward as previously stated		618,801	251,929	870,730	1,290,440
Prior Year Adjustment		140,442	-	140,442	140,442
Total funds brought forward as restated		759,243	251,929	1,011,172	1,430,882
Total funds carried forward	13	706,427	231,975	938,402	1,011,172

There were no recognised gains or losses other than those shown in the above statement of financial activities. The results for the above financial periods derive from continuing operations.

ORCHID CANCER APPEAL

BALANCE SHEET

As at 30 September 2019

		30 September 2019		30 September 2018	
	Notes	£	£	£	£
Fixed Assets					
Tangible Assets	10		-		-
Current Assets					
Cash at bank and in hand		84,979		101,471	
Investments – cash deposits		973,744		1,163,031	
Debtors	11	<u>187,046</u>		<u>129,589</u>	
		1,245,769		1,394,091	
Creditors					
Amounts due within one year	12	<u>(307,367)</u>		<u>(382,919)</u>	
Net Current Assets			938,402		1,011,172
Total Assets less Current Liabilities			938,402		1,011,172
Net Assets			938,402		1,011,172
Represented by:					
General Unrestricted Funds	13	334,804		303,777	
Unrestricted Designated Funds	13	<u>371,623</u>		<u>455,466</u>	
			706,427		759,243
Restricted Funds	13	<u>231,975</u>		<u>251,929</u>	
		938,402		1,011,172	

The company is limited by guarantee.

The financial statements have been prepared in accordance with the special provisions of Part 15 of the Companies Act 2006 relating to small companies.

The financial statements were approved by the Board and authorised for issue on 22 September 2020 and signed on its behalf by:



Mr C S Osborne

Company number 3963360

ORCHID CANCER APPEAL

STATEMENT OF CASH FLOWS

For the year ended 30 September 2019

	Year ended 30 September 2019		Year ended 30 September 2018	
	£	£	£	£
Cash flows from operating activities:				
Net income/(expenditure)	(72,770)		(419,710)	
Adjustments for:				
Depreciation	-		2,106	
Interest	(9,981)		(12,470)	
(increase)/decrease in debtors	(57,457)		42,164	
Decrease in creditors	<u>(75,553)</u>		<u>(62,581)</u>	
Net cash used in operating activities		(215,761)		(450,491)
Cash flows from investing activities:				
Interest	9,981		12,470	
Disposal/(purchase) of investments (deposits more than 3 months)	<u>143,440</u>		<u>(5,270)</u>	
Net cash provided by investing activities		153,421		7,200
Change in cash and cash equivalents		<u>(62,340)</u>		<u>(443,291)</u>
Cash and cash equivalents at the beginning of the year		208,762		652,053
Cash and cash equivalents at the end of the year		<u>146,422</u>		<u>208,762</u>
Analysis of cash and cash equivalents				
Cash at bank and in hand		84,979		101,471
Notice deposits of less than 3 months		61,443		107,291
		<u>146,422</u>		<u>208,762</u>

ORCHID CANCER APPEAL

NOTES TO THE FINANCIAL STATEMENTS

For the year ended 30 September 2019

1. ACCOUNTING POLICIES

These financial statements have been prepared under the historical cost convention and in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102). The Charity is a public benefit entity for the purposes of FRS 102 and therefore has also prepared the financial statements in accordance with the Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (The FRS 102 Charities SORP) and the Charities Act 2011.

Going Concern

The trustees have assessed whether the use of the going concern assumption is appropriate in preparing these financial statements. The trustees have made this assessment in respect to a period of one year from the date of approval of these financial statements and have considered the impact of the coronavirus pandemic on the charity's operations. In particular the trustees have considered the charities forecasts and projections and have taken account of pressures on donation income. After making enquiries the trustees have concluded there is a degree of uncertainty around donation income for 2020/21 however that there is a reasonable expectation that the charity has adequate resources to continue in operational existence for the foreseeable future. The charity therefore continues to adopt the going concern basis in preparing its financial statements.

Functional Currency

The functional currency is considered to be in pounds sterling because that is the currency of the primary economic environment in which the Charity operates. The financial statements are also presented in pounds sterling, rounded to the nearest £1.

Taxation

The Charity has suffered no tax charge as it is not subject to UK Corporation tax on its charitable activities.

Depreciation

Depreciation is provided at the following annual rates so as to write off the cost of each asset over its useful life. Assets with a purchase consideration in excess of £1,000 are capitalised.

Computer and Office Equipment - 33 1/3% on written down value

Funds Accounting

General funds are unrestricted funds available for use at the discretion of the Trustees in furtherance of the general activities of the Charity and which have not been designated for other purposes.

Designated funds comprise funds which have been set aside at the discretion of the Trustees for specific purposes.

Restricted funds are funds subject to specific restrictions imposed by donors or by the nature of the appeal. The purpose and use of the Charity's restricted funds is set out in the notes to the financial statements.

Income

Income becoming available to the Charity is recognised when there is entitlement to the income, probability of receipt and amounts can be measured reliably as per FRS102 SORP.

Gifts in kind are valued and brought in as income and the appropriate expenditure, when the items are used/distributed. The values attributable to gifts in kind are an estimate of the gross value to the organisation, where quantifiable. Where this intangible income relates to project activities, it is included as an activity in furtherance of the Charity's objects.

Expenditure

Cost of raising funds includes costs associated with the fund-raising events in furtherance of the Charity's objects.

Charitable expenditure includes costs associated with particular activities in furtherance of the Charity's objects.

Governance costs are those incurred in connection with the management of the Charity's assets, organisational administration, and compliance with constitutional and statutory requirements and are included within support costs.

ORCHID CANCER APPEAL

NOTES TO THE FINANCIAL STATEMENTS

For the year ended 30 September 2019

Expenditure (cont'd)

Charitable expenditure comprises direct expenditure including direct staff costs attributable to the activity. Support costs which cannot be directly attributed to an activity have been allocated to activities on a basis consistent with use of the resources.

Grants payable are charged when the offer is conveyed to the recipient except in those cases where the offer is conditional, such grants being recognised as expenditure when the conditions attaching are fulfilled. Grants offered subject to conditions which have not been met at the balance sheet date are noted as a commitment, but not accrued as expenditure.

Financial Instruments

The charitable company has elected to apply the provisions of Section 11 'Basic Financial Instruments' of FRS 102 to all of its financial instruments. Financial instruments are recognised in the Charity's balance sheet when the Charity becomes party to the contractual provisions of the instrument. Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously. With the exceptions of prepayments, deferred income and amounts owed to or from HMRC. All other debtor and creditor balances are considered to be basic financial instruments under FRS 102.

Debtors

Short term debtors are measured at transaction price, less any impairment. Loans receivable are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method, less any impairment.

Cash and Cash equivalents

Cash and cash equivalents in the balance sheet comprise cash at banks and in hand and term deposits with an original maturity date of three months or less. For the purpose of the statement of cash flows, cash and cash equivalents consist of cash and cash equivalents as defined above.

Creditors

Short term trade creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method. Deferred income represents grants, contract funding and training fees relating to future periods.

Pension Scheme

The Charity operates a defined contribution stakeholder pension scheme. The amount charged to the statement of financial activities in respect of pension costs is the Charity's contributions payable in the year. The assets of the scheme are held separately from the Charity. There was no outstanding liability owed to the scheme at the end of the current or prior years.

Employee Benefits

The cost of short-term employee benefits are recognised as a liability and an expense. The cost of any material unused holiday entitlement is recognised in the period in which the employee's services are received.

Critical accounting estimates and areas of judgement

In the view of the Trustees in applying the accounting policies adopted, no judgements were required that have significant effect on the amounts recognised in the financial statements nor do any estimates or assumptions carry a significant risk of material adjustment in the next financial year.

ORCHID CANCER APPEAL

NOTES TO THE FINANCIAL STATEMENTS

For the year ended 30 September 2019

2. Donations

Current year

		Year ended 30 September 2019		
	Note	Unrestricted £	Restricted £	Total £
Individuals		56,468	-	56,468
Corporates (this includes Gifts in Kind)		91,076	29,000	120,076
Trusts & Foundations		9,550	151,515	161,065
Fundraising Events	3	<u>312,526</u>	-	312,526
Total		<u>469,620</u>	<u>180,515</u>	650,135

Prior Year

		Year ended 30 September 2018		
		Unrestricted £	Restricted £	Total £
Individuals		51,940	-	51,940
Legacies		34,286	-	34,286
Corporates (this includes Gifts in Kind)		23,485	-	23,485
Trusts & Foundations		24,050	199,455	223,505
Fundraising Events		<u>330,894</u>	-	330,894
Total		<u>464,655</u>	<u>199,455</u>	664,110

ORCHID CANCER APPEAL

NOTES TO THE FINANCIAL STATEMENTS

For the year ended 30 September 2019

3. Fundraising events

	Year ended 30 September 2019			Year ended 30 September 2018
	Unrestricted £	Restricted £	Total £	Total £
Cycling, Running and Trek Events	127,172	-	127,172	175,144
Third party Organised Events	159,279	-	159,279	117,876
Other	26,075	-	26,075	37,874
Total	312,526	-	312,526	330,894

All fundraising events in 2018 were unrestricted.

4. Charitable Activities

	Year ended 30 September 2019			Year ended 30 September 2018
	Unrestricted £	Restricted £	Total £	Total £
Grants – Big Lottery Reaching Communities Fund	-	132,526	132,526	121,133
North East London Cancer Network	-	50,000	50,000	-
Other	-	3,000	3,000	-
Total	-	185,526	185,526	121,133

In the prior year £121,133 of Grants were restricted.

ORCHID CANCER APPEAL

NOTES TO THE FINANCIAL STATEMENTS

For the year ended 30 September 2019

5. Total Expenditure

	Fundraising & Communications	Education & Awareness	Research	Year ended 30 September 2019 Total £	Year ended 30 September 2018 Total £
	£	£	£	£	£
Grants	-	-	41,545	41,545	200,300
Staff costs	97,131	252,263	24,359	373,753	482,413
Fundraising expenses	107,362	-	-	107,362	125,335
Information materials	-	131,634	-	131,634	68,191
Direct Costs	-	93,154	-	93,154	164,398
	204,493	477,051	65,813	747,357	1,040,637
<i>Support costs</i>					
Depreciation	-	-	-	-	2,106
Other	38,137	103,389	9,564	151,090	155,908
Governance – staff costs	2,874	7,465	721	11,060	9,123
Governance – audit fees	2,381	6,454	597	9,432	10,688
	43,392	117,308	10,882	171,582	177,825
Total Expenditure	247,885	594,359	76,695	918,939	1,218,462
Prior Year	369,568	614,320	234,574	1,218,462	

ORCHID CANCER APPEAL

NOTES TO THE FINANCIAL STATEMENTS

For the year ended 30 September 2019

6. Grants Awarded

	Year ended 30 September 2019 £	Restated Year ended 30 September 2018 £
Grant commitments brought forward	249,616	367,523
Institutional grants for medical research awarded during year:		
- Orchid Study & Travel Awards	970	300
- Barts & London School of Medicine	83,843	200,000
Grants written back in the year	(43,360)	-
Payments made during year	(92,067)	(318,207)
Grant commitments carried forward	<u>199,002</u>	<u>249,616</u>
Payable less than one year	<u>199,002</u>	<u>249,616</u>

7. Taxation

The charitable company is exempt from corporation tax as all its income is charitable and is applied for charitable purposes.

8. Net expenditure for the year

This is stated after charging:

	Year ended 30 September 2019 £	Year ended 30 September 2018 £
Depreciation	-	2,106
Auditor's remuneration:		
Statutory audit (excluding VAT)	8,402	8,220
Other Services	1,030	546

ORCHID CANCER APPEAL

NOTES TO THE FINANCIAL STATEMENTS

For the year ended 30 September 2019

9. Staff costs and numbers

Staff costs were as follows:

	Year ended 30 September 2019	Year ended 30 September 2018
	£	£
Salaries and wages	222,273	298,443
Social security costs	21,968	30,634
Pension contributions	2,174	2,972
Total employee costs	<u>246,415</u>	332,049
Consultants' costs	<u>138,398</u>	159,488
	<u><u>384,813</u></u>	491,537

During the year ended 30 September 2019 one employee earned between £80,000 and £89,999 (year ended to 30 September 2018: one employee earned between £80,000-£89,999). The pension contributions paid in respect of this employee totalled £2,014 (2018: £1,207).

The key management personnel of the Charity comprise the Trustees and the Chief Executive.

The Trustees do not receive remuneration. The total remuneration of the key management personnel, including employer pension contributions and employer national insurance contributions, was £92,476 (year ended 30 September 2018: £91,530).

The average number of employees during the year on a headcount basis was as follows:

	Year ended 30 September 2019	Year ended 30 September 2018
Fundraising	0.8	2.1
Education and Awareness	3.5	5.0
Grant support	0.3	0.3
	<u>4.6</u>	7.4

ORCHID CANCER APPEAL

NOTES TO THE FINANCIAL STATEMENTS

For the year ended 30 September 2019

10. Tangible fixed assets

	30 September 2019
Cost	£
At the start of the year	25,678
Additions	<u>(23,003)</u>
At the end of the year	<u>2,675</u>
Depreciation	
At the start of the year	25,678
Charge for the year	<u>(23,003)</u>
At the end of the year	<u>2,675</u>
Net book value	
At the end of the year	<u><u>-</u></u>
At the start of the year	<u><u>-</u></u>

Fixed assets during the current year and prior year comprised computer and office equipment.

11. Debtors

	30 September 2019	30 September 2018
	£	£
Prepayments	35,060	51,179
Other debtors and accrued income	<u>151,986</u>	<u>78,410</u>
	<u><u>187,046</u></u>	<u><u>129,589</u></u>

12. Creditors: amounts due within one year

	30 September 2019	Restated 30 September 2018
	£	£
Grants payable (note 6)	199,002	390,058
Trade & Other Creditors	61,885	89,698
Taxation and Social Security	6,311	8,509
Accruals	<u>40,169</u>	<u>35,096</u>
	<u><u>307,367</u></u>	<u><u>523,361</u></u>

ORCHID CANCER APPEAL

NOTES TO THE FINANCIAL STATEMENTS

For the year ended 30 September 2019

13. Movements in funds

Current year

	Brought Forward £	Income £	Expenditure £	Carried forward £
Unrestricted				
General	303,777	480,128	(449,101)	334,804
Designated – Research	250,000	-	(83,843)	166,157
Designated – Development	121,808	-	-	121,808
Designated – Awareness	83,658	-	-	83,658
Total Unrestricted	759,243	480,128	(532,944)	706,427
Restricted				
Testicular Cancer Counselling	19,226	-	(2,979)	16,247
Male Cancer Nurse Information				
Specialist-Other funders	88,499	3,000	(14,793)	76,706
Awareness	242	19,750	(19,992)	-
Prostate Cancer Nurse	10,000	-	(10,000)	-
'Awards for All' Penile Cancer grant	9,960	5,000	(10,468)	4,492
Student Study & Travel				
Scholarships	7,700	-	(971)	6,729
Big Lottery Reaching Communities Fund	69,664	135,526	(153,721)	51,469
Roadshows	25,057	81,815	(75,946)	30,926
Tissue Bank	-	38,950	(38,950)	-
Young Person's Testicular Cancer Project	12,381	-	(2,012)	10,369
Prostate Cancer Awareness Services	9,200	29,000	(38,200)	-
	-	3,000	(3,000)	-
North East London Cancer Network				
	-	50,000	(14,963)	35,037
Total Restricted	251,929	366,041	(385,995)	231,975
Total Funds 2019	1,011,172	846,169	(918,939)	938,402

ORCHID CANCER APPEAL

NOTES TO THE FINANCIAL STATEMENTS

For the year ended 30 September 2019

Movements in funds

Prior year	Restated Brought Forward £	Income £	Expenditure £	Carried forward £
Unrestricted				
General	566,969	478,164	(741,356)	303,777
Designated – Research	450,000	-	(200,000)	250,000
Designated – Development	121,808	-	-	121,808
Designated – Awareness	83,658	-	-	83,658
Total Unrestricted	1,222,435	478,164	(941,356)	759,243
Restricted				
Testicular Cancer Awareness	6,271	-	(6,271)	-
Testicular Cancer Counselling	20,015	-	(789)	19,226
Male Cancer Nurse Information Specialist-Other funders	8,780	88,500	(8,781)	88,499
Awareness	1,980	24,500	(26,238)	242
Prostate Cancer Nurse	20,000	-	(10,000)	10,000
'Awards for All' Penile Cancer grant	-	9,960	-	9,960
Student Study & Travel Scholarships	8,000	-	(300)	7,700
Big Lottery Reaching Communities Fund	67,158	121,133	(118,627)	69,664
Roadshows	53,868	43,595	(72,406)	25,057
Tissue Bank	-	7,000	(7,000)	-
Young Person's Testicular Cancer Project	22,375	16,700	(26,694)	12,381
Prostate Cancer Awareness	-	9,200	-	9,200
Total Restricted	208,447	320,588	(277,106)	251,929
Total Funds 2018	1,430,882	798,752	(1,218,462)	1,011,172

General funds are unrestricted funds available for use at the Trustees' discretion in furtherance of the general activities of the Charity and which have not been designated for other purposes.

Designated Research funds represent monies set aside at the Trustees' discretion to be used to help fund the costs of future research programmes.

Designated Development funds represent monies set aside at the Trustees' discretion to be used to help fund the costs related to increasing the organisational capacity of the Charity.

Designated Awareness funds represent monies set aside at the Trustees' discretion to be used to help fund specific awareness activities.

ORCHID CANCER APPEAL

NOTES TO THE FINANCIAL STATEMENTS

For the year ended 30 September 2019

14. Analysis of net assets between funds

Current year

	Unrestricted Funds £	Restricted Funds £	Total funds at 30 September 2019 £
Current Assets	1,013,794	231,975	1,245,769
Creditors due within one year	(307,367)	-	(307,367)
Net assets at 30 September 2019	706,427	231,975	938,402

Prior year

	Unrestricted Funds £	Restricted Funds £	Restated Total funds at 30 September 2018 £
Current Assets	1,142,162	251,929	1,394,091
Creditors due within one year	(382,922)	-	(382,922)
Net assets at 30 September 2018	759,243	251,929	1,011,172

15. Related party transactions

No Trustees gave donations to the Charity in the year (2018: £nil).

There were no other related party transactions during the current or prior year.

16. Financial commitments

The Charity was committed to making the following payments under non-cancellable operating leases.

	Year ended 30 September 2019 £	Year ended 30 September 2018 £
Due within one year	18,300	-
Due within one to two years	-	-

ORCHID CANCER APPEAL

NOTES TO THE FINANCIAL STATEMENTS

For the year ended 30 September 2019

17. Prior year adjustment

An adjustment to release grant provisions made in excess of external third-party commitments awarded.

	£
Net assets brought forward at 1 st October 2015 as previously reported	1,290,440
Grant adjustment	<u>140,442</u>
Net assets brought forward at 1 st October 2016 as restated	<u>1,430,882</u>

18. Post balance sheet events

The accounts have been approved during a period where there is much uncertainty as a result of the emergence and international spread of a coronavirus (COVID-19). The trustees consider that this is a non-adjusting post balance sheet event because the impact on the charity in 2020 has been significant but no adjustments are required to these financial statements as a result of the matter identified.